- |||||||||| ABP-300 / Abpro Therap, BIO invest, Mabwell (Shanghai) Biosci
Clinical, P1 data, PK/PD data, Journal: Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: A Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody. (Pubmed Central) - Sep 1, 2021
P1, P2, P2
The positive rates of serum ADAs and antibody titers were low with no evidence of an impact on safety or PK. In conclusion, MW33 was well-tolerated, demonstrated linear PK, with a lower positive rate of serum ADAs and antibody titers in healthy subjects.Trial registration: ClinicalTrials.gov identifier: NCT04427501..Trial registration: ClinicalTrials.gov identifier: NCT04533048..Trial registration: ClinicalTrials.gov identifier: NCT04627584..
- |||||||||| ABP-300 / Abpro, BIO invest, Mabwell (Shanghai) Biosci
Enrollment open: A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19 (clinicaltrials.gov) - Feb 25, 2021
P2, N=150, Recruiting,
In conclusion, MW33 was well-tolerated, demonstrated linear PK, with a lower positive rate of serum ADAs and antibody titers in healthy subjects.Trial registration: ClinicalTrials.gov identifier: NCT04427501..Trial registration: ClinicalTrials.gov identifier: NCT04533048..Trial registration: ClinicalTrials.gov identifier: NCT04627584.. Not yet recruiting --> Recruiting
- |||||||||| ABP-300 / Abpro, BIO invest, Mabwell (Shanghai) Biosci
Trial completion: A Clinical Study to Evaluate MW33 Injection (clinicaltrials.gov) - Feb 25, 2021
P1, N=42, Completed,
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| ABP-300 / Abpro, BIO invest, Mabwell (Shanghai) Biosci
Enrollment closed, Enrollment change: A Clinical Study to Evaluate MW33 Injection (clinicaltrials.gov) - Sep 2, 2020
P1, N=42, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=32 --> 42
|
